Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Neoadjuvant Intravesical Nadofaragene Firadenovec With Enfortumab Vedotin and Pembrolizumab for the Treatment of Muscle Invasive Bladder Cancer, TRIFECTA Trial (TRIFECTA)

9 novembre 2026 mis à jour par: University of Washington

Intravesical Nadofaragene Firadenovec With Enfortumab Vedotin and Pembrolizumab in Patients With Muscle Invasive Bladder Cancer (TRIFECTA)

This phase II trial tests the effect of intravesical nadofaragene firadenovec in combination with enfortumab vedotin and pembrolizumab before (neoadjuvant) radical cystectomy in treating patients with muscle invasive bladder cancer. The combination of enfortumab vedotin and pembrolizumab are already considered standard of care in the treatment of muscle invasive bladder cancer. This trial attempts to determine whether the addition of nadofaragene firadenovec to the current standard regiment is safe and can improve oncological outcomes for those with muscle invasive bladder cancer.

Nadofaragene firadenovec, a type of intravesical gene therapy, is a weakened adenovirus that carries a copy of the gene for interferon alfa-2b. This medication gets absorbed by the bladder and stimulates the bladder to naturally create interferon alfa-2b, which is thought to kill bladder cancer. Nadofaragene firadenovec is given in a solution that is placed directly into the bladder (intravesical) using a thin tube called a catheter. It is a medication that is already Food and Drug Administration approved for the treatment of non-muscle invasive bladder cancer.

Enfortumab vedotin is a monoclonal antibody, enfortumab, linked to an anticancer drug called vedotin. It works by helping the immune system to slow or stop the growth of tumor cells. Enfortumab attaches to a protein called nectin-4 on tumor cells in a targeted way and delivers vedotin to kill them. It is a type of antibody-drug conjugate.

Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread.

Investigators aim to assess whether adding intravesical nadofaragene firadenovec to the current recommended treatment of enfortumab vedotin and pembrolizumab before undergoing a radical cystectomy may be safe, tolerable, and/or effective in treating patients with muscle-invasive bladder cancer.

Aperçu de l'étude

Description détaillée

OUTLINE:

Patients receive standard of care neoadjuvant therapies for muscle invasive bladder cancer including: enfortumab vedotin intravenously (IV) on days 1 and 8 and pembrolizumab IV on day 1 of each cycle. Cycles repeat every 21 days for up to 3-4 cycles in the absence of disease progression or unacceptable toxicity. In addition, patients will also receive nadofaragene firadenovec intravesically on day 1 of cycle 1 (one total dose during the entire neoadjuvant period). Starting 4-8 weeks after completion of treatment, patients undergo radical cystectomy (RC) per standard clinical care. Additionally, patients undergo urine and blood sample collection and computed tomography (CT), magnetic resonance imaging (MRI) or positron emission tomography (PET)/CT throughout the study.

After completion of study treatment, patients are followed for up to 30 days post-cystectomy to monitor for adverse events.

Type d'étude

Interventionnel

Inscription (Estimé)

24

Phase

  • Phase 2

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

  • Nom: Jonathan Wright, MD
  • Numéro de téléphone: 206-598-4294
  • E-mail: jlwright@uw.edu

Lieux d'étude

    • Washington
      • Seattle, Washington, États-Unis, 98109
        • Fred Hutch/University of Washington Cancer Consortium
        • Chercheur principal:
          • Jonathan Wright, MD
        • Contact:
          • Jonathan Wright, MD
          • Numéro de téléphone: 206-598-4294
          • E-mail: jlwright@uw.edu

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Age ≥ 18 years at the time of screening
  • Ability to understand and willingness to sign the written informed consent document
  • Patients with confirmed muscle-invasive urothelial carcinoma of the bladder (cT2-4a, N0-1, M0 or cT1, N1, M0), who are planning to undergo RC
  • Pure urothelial or mixed histologic subtypes are allowed if urothelial is the primary histology (regardless of the % of conventional urothelial histology; however, any % of small cell/neuroendocrine is excluded)
  • Eligible to receive neoadjuvant enfortumab vedotin and pembrolizumab (EV-P) per the patient's medical oncologist's discretion
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-2
  • Hemoglobin ≥ 9 g/dL
  • Absolute neutrophil count of ≥ 1500 cells/uL
  • Platelet count of ≥ 100,000/uL
  • Alanine and aspartate aminotransferase levels ≤ 2.5 x upper limit of normal (ULN)
  • Total bilirubin ≤ 1.5 x ULN (≤ 2.5 x ULN for Gilbert syndrome)
  • Creatinine clearance or estimated glomerular filtration rate (GFR) ≥ 30ml/min (using Chronic Kidney Disease Epidemiology Collaboration Formula [CKD-EPI] 2021 or Cockcroft-Gault equation)
  • For patients with evidence of, or history of HIV, chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infection, the viral load must be undetectable, or the infection must have been treated and cured. Patients are not allowed to be on therapy agents given for HIV, HBV or HCV. Routine testing for HIV, HBV and HCV is not required for patients without such history unless clinically indicated
  • Individuals with prior malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are allowed to enroll

Exclusion Criteria:

  • cT4b, N2-3, or M1 clinical stage at time of screening
  • Any known concurrent clinically relevant malignancies (discussion with trial principal investigator [PI] can be considered)
  • Prior systemic therapy for MIBC or non-muscle invasive bladder carcinoma (NMIBC)
  • Current or prior use of systemic immunosuppressive medication within 14 days before first dose of investigational product. The following are allowed (not systemic route): intranasal, inhaled, intra-auricular, intra-articular, topical steroids, local steroid injections
  • Pure non-urothelial histology subtype/variant or any neuroendocrine (small or large cell) component
  • Prior treatment with adenovirus-based drugs
  • Known hypersensitivity or allergy to any components of rAd-interferon (IFN)a/Syn3
  • Currently receiving other investigational agent
  • Pregnant or lactating women
  • Inability to comprehend and provide informed consent

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: N / A
  • Modèle interventionnel: Affectation à un seul groupe
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Treatment

Patients receive standard of care neoadjuvant therapies for muscle invasive bladder cancer including: enfortumab vedotin IV on days 1 and 8 and pembrolizumab IV on day 1 of each cycle. In addition, patients also receive nadofaragene firadenovec intravesically on day 1 of cycle 1 (total of 1 dose in neoadjuvant period). Cycles repeat every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Starting 4-8 weeks after treatment, patients undergo RC per standard clinical care. Additionally, patients undergo urine and blood sample collection and CT, MRI or PET/CT throughout the study.

Undergo MRI

Autres noms:
  • IRM

Given IV

Autres noms:
  • Keytruda

Undergo CT or PET/CT

Autres noms:
  • TDM
  • Scanner
  • Tomodensitométrie

Undergo PET/CT

Autres noms:
  • ANIMAUX
  • TEP-scan

Given IV

Autres noms:
  • Padčev
  • AGS-22M6E
  • Anti-nectine 4 ADC ASG-22CE
  • Conjugué anticorps monoclonal anti-nectine-4-médicament AGS-22M6E
  • ASG22CE

Undergo urine and blood sample collection

Autres noms:
  • Collecte d'échantillons biologiques

Given intravesically

Autres noms:
  • Adstiladrine
  • Instiladrin
  • Adenovirus recombinant-interféron SCH 721015
  • Adenovirus recombinant-Interféron avec Syn3
  • Adénovirus recombinant-Interféron/Syn3
  • SCH 721015

Undergo RC

Autres noms:
  • CR

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Proportion of patients who receive nadofaragene firadenovec and complete at least 2 cycles of enfortumab vedotin and pembrolizumab in the neoadjuvant period followed by radical cystectomy
Délai: Within 10 weeks from last neoadjuvant therapy dose

Will be calculated as the number of patients who complete the planned course divided by the total number of enrolled patients who initiate therapy. Exact 95% confidence intervals will be reported. Reasons for non-completion will be summarized descriptively.

Within 10 weeks from last neoadjuvant therapy dose

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Incidence of grade 3 or higher treatment-related adverse events (AE)
Délai: From initiation of neoadjuvant systemic therapies (day 1 of cycle 1; 4 cycles total; each cycle is 21 days), through 30 days post-RC (RC occurs approximately 4-8 weeks after completion of neoadjuvant systemic therapies)

Will be graded by provider-scored toxicity via the Common Terminology Criteria for Adverse Events (CTCAE) version 6.0. Will be summarized descriptively, including the number and proportion of patients experiencing at least one grade ≥ 3 AE, and the type, severity, and relatedness of all treatment-related AEs, attributed by agent.

From initiation of neoadjuvant systemic therapies (day 1 of cycle 1; 4 cycles total; each cycle is 21 days), through 30 days post-RC (RC occurs approximately 4-8 weeks after completion of neoadjuvant systemic therapies)
Incidence of AEs
Délai: From initiation of neoadjuvant systemic therapies (day 1 of cycle 1; 4 cycles total; each cycle is 21 days), through 30 days post-RC (RC occurs approximately 4-8 weeks after completion of neoadjuvant systemic therapies)

Will be summarized by maximum CTCAE grade and relatedness to the treatment.

From initiation of neoadjuvant systemic therapies (day 1 of cycle 1; 4 cycles total; each cycle is 21 days), through 30 days post-RC (RC occurs approximately 4-8 weeks after completion of neoadjuvant systemic therapies)
Pathologic complete response (pCR) on radical cystectomy (RC) specimen
Délai: At time of radical cystectomy (RC), approximately 4-8 weeks following completion of neoadjuvant systemic therapies

Will be defined as the proportion of participants achieving ypT0N0. Will assume the null hypothesis that the true pCR rate is 56 % with the alternative hypothesis of 65%. The observed pCR rate will be reported with an exact 95% confidence interval using the Clopper-Pearson method.

At time of radical cystectomy (RC), approximately 4-8 weeks following completion of neoadjuvant systemic therapies
Downstaging (≤ ypT1N0) on RC specimen
Délai: At time of RC, approximately 4-8 weeks following completion of neoadjuvant systemic therapies
At time of RC, approximately 4-8 weeks following completion of neoadjuvant systemic therapies

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Collaborateurs

Les enquêteurs

  • Chercheur principal: Jonathan Wright, MD, Fred Hutch/University of Washington Cancer Consortium

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Estimé)

1 décembre 2026

Achèvement primaire (Estimé)

1 juin 2027

Achèvement de l'étude (Estimé)

1 juillet 2027

Dates d'inscription aux études

Première soumission

6 janvier 2026

Première soumission répondant aux critères de contrôle qualité

8 janvier 2026

Première publication (Réel)

12 janvier 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

13 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

9 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Oui

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner